GSK boosts lung cancer portfolio with $10.6 billion Nuvalent takeover

June 9 (Reuters) – British drugmaker GSK on Tuesday agreed to acquire U.S.-listed cancer drug developer Nuvalent for $10.6 billion to boost its lung cancer portfolio. The all-cash deal values Nuvalent

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)